A stepwise library-based strategy has been employed to acquire a potent ligand for the SH3 domain of Fyn, a Src kinase family member that plays a key role in T cell activation. The easily automated methodology is designed to identify potential interaction sites that circumscribe the protein/peptide binding region on the SH3 domain. The library protocol creates peptide/ nonpeptide chimeras that are able to bind to these interaction sites that are otherwise inaccessible to natural amino acid residues. The peptide-derived lead and the Fyn-SH3 domain form a complex that exhibits a K D of 25 ± 5 nM, approximately 1000-fold more potent than that displayed by the corresponding conventional peptide ligand. Furthermore, the lead ligand exhibits selectivity against SH3 domains derived from other Src kinases, in spite of a sequence identity of approximately 80%.
Introduction
The Src homology 3 (SH3) domain is one of many protein recognition modules that play an essential role in the operation of signaling pathways [1] [2] [3] . Like all protein recognition units, the SH3 domain exhibits a marked preference for a particular consensus sequence of amino acid residues, namely, a proline-rich motif of the general form Pro-Xaa-Xaa-Pro [4] . The molecular basis for the proline-based sequence preference has been resolved via the structural elucidation of several SH3 domain/peptide ligand complexes. The peptide ligand is bound as a type II polyproline helix. Side chains on every third residue of the helix are oriented in the same direction. Two of these side chains are positioned into hydrophobic pockets of the SH3 domain. In addition, other residues of the peptide ligand are also able to productively interact with the SH3 domain. One of the interesting aspects of the polyproline helix structure is that the ligand can associate with the binding pocket in an N-to-C orientation or in the opposite sense [5] . The relative bound orientation is dictated by the presence of a positively charged residue on either the N terminus of the peptide ligand ("Type I") or at the corresponding C terminus ("Type II").
More than 400 different SH3 domains are encoded within the human genome. Consequently, even at this early stage in the analysis of the human proteome, it is not surprising that these domains have been implicated in a variety of normal and abnormal physiological processes [6] . At the biochemical level, SH3 domains have *Correspondence: dlawrenc@aecom.yu.edu been shown to regulate enzymatic activity as well as promote the assembly of signaling complexes. For example, all nine members of the Src family of protein kinases contain the general structure (N terminus)-SH3-SH2-SH1-(C terminus) [7] . The SH3 domain not only serves as an intramolecular on/off switch that controls kinase activity, but also acts as a targeting moiety that directs Src kinase family members to the proper intracellular sites and substrates. SH3 domains are present in a variety of different proteins, including other tyrosine kinases, such as Abl and Crk; protein phosphatases, such as SHP-1; and adaptor proteins, such as Grb2 and Sos.
Many studies that seek to correlate the activity of a given signaling protein with cellular phenotype typically resort to the tools of molecular biology to create constitutively active, dominant-negative, or other analogs of the corresponding wild-type protein. Although this general strategy is a powerful one, deletion of the natural protein or expression of mutated analogs can result in complications arising from compensation by closely related proteins, inappropriate localization of the protein analog, or unintended modulation of other signaling pathways. In contrast to genetically expressed protein analogs, inhibitors or synthetic ligands rapidly perturb the wild-type protein, which is present in its natural state in terms of quantity, activity, and location. In this regard, SH3 domain-selective ligands are a much soughtafter commodity. Unfortunately, the widespread presence of SH3 domains throughout the human proteome and their generally similar ligand recognition profiles renders this task a formidable one. In addition, several studies have demonstrated that conventional peptide ligands, consisting of standard amino acid (>10) residues, generally exhibit modest affinities (low M) and low selectivities for their intended SH3 domain targets [8] [9] [10] [11] . Indeed, protein interaction domains, in general, exhibit only moderately robust affinities for their endogenous ligands, a not too surprising observation given the fact that the protein-protein interactions that drive signaling cascades are transient by necessity.
We report, in this study, the synthesis and identification of a peptide-derived ligand that selectively targets the Fyn-SH3 domain. Fyn, a member of the Src tyrosine protein kinase family, is known to play an important role in the biochemical cascade responsible for T cell activation [12] . Both Fyn and its closely related counterpart, Lck, exhibit similar substrate specificities, and the SH2/SH3 domains of both proteins play key roles in thymic development and T cell proliferation in response to antigenic challenges. In particular, the SH3 domains of both have been shown to interact with the Wiskott Aldrich Syndrome protein (WASp) in vitro [13] . To the best of our knowledge, this is the first report of a ligand that is able to discriminate between SH3 domains of the members of the Src kinase family.
Results and Discussion
The consensus sequences for a number of SH3 domains have been reported. However, peptides (deca- The protocol seeks to identify potential interaction sites that circumscribe the peptide binding on the SH3 domain that are otherwise inaccessible to conventional amino acid residues. The final synthetic step, namely, cleavage of the modified peptide from the resin with assay buffer, delivers the library in an assay-ready form.
peptides and longer) bearing these sequences serve as relatively modest SH3 domain ligands (M range). A number of attempts have been made to enhance the affinities of SH3 domain-directed peptides, either by searching for optimized sequences via library methods or by the introduction of nonnatural substituents at the N or C termini [8] [9] [10] [11] . However, these strategies typically do not furnish ligands that exhibit affinities significantly beyond the M/nM border. By contrast, Lim and his colleagues have demonstrated that N-substituted peptides ("peptoids") exhibit high affinities and good selectivities for specific classes of SH3 domains [14, 15] . The critical design element in these studies is the notion that N-substituted glycine residues serve as proline mimetics and, given the diversity inherent within the former, can be screened to identify substituents that dramatically enhance SH3 domain affinity. Peptoid ligands that exhibit nM affinities were identified for the SH3 domains of Grb2 (N terminus; K D = 30 nM), Src (K D = 140 nM), and Crk (K D = 8 nM) [14, 15] . Furthermore, these ligands exhibit a high selectivity in favor of their targeted SH3 domain in spite of the fact that these domains are structurally homologous (e.g., Crk and Src SH3 domains display a 33% sequence similarity) [16] . These results dispel the previously held notion that it is not possible to obtain tight binding ligands for SH3 domains due to the small size (60 amino acids).
We have previously described an iterative librarybased strategy that converts low-affinity consensus sequence peptides into high-affinity species that display pronounced selectivities for their intended protein targets [17] [18] [19] [20] . The methodology, as illustrated in general form in Figure 1 , has been successfully applied to SH2 domains, protein tyrosine phosphatases, and protein kinases, including specific isoforms of the highly conserved protein kinase C subfamily. However, the strategy relies upon identifying a series of unique and widely interspersed interaction sites on the protein surface.
Given the small size of SH3 domains, it was far from clear whether proteins of this size would be amenable to such an approach. We decided to explore this question by employing the SH3 domain of the Fyn tyrosine kinase as our target. Fyn is a member of the Src kinase family, a group of highly homologous tyrosine kinases. The extremely high sequence homology displayed by the SH3 domains from these proteins represents a serious challenge in terms of acquiring selective inhibitors (e.g., the SH3 domains of Src and Fyn are 78% identical [21] ). To the best of our knowledge, there are no examples of ligands that distinguish between the SH3 domains of the Src kinase family.
A good portion of the binding energy that drives SH3 domain/consensus sequence complex formation results from the interaction of key residues on the consensus sequence peptide with hydrophobic pockets of the SH3 domain. However, adjacent residues can also contribute binding energy by engaging in noncovalent interactions with subsites located proximal to these lipophilic pockets. The methodology described in Figure  1 allows one to screen for substituents positioned on the peptide ligand that can engage in interactions with the SH3 domain, which are simply not accessible to naturally occurring amino acid residues. The consensus sequence peptide 1 was prepared on a disulfidelinked Tentagel resin. One of the residues in 1 contains (L)-2,3-diaminopropionic acid 2 (Dap), which possesses an amine handle on the side chain that can be readily modified with an array of activated carboxylic acid moieties. Peptide-resin 1 was then distributed, in equal amounts, into individual wells of eight 96-well synthesis plates. Each well was subsequently charged with a single carboxylic acid from a total library of 720 different commercially available carboxylic acids that vary in size, shape, polarity, and charge. Following acylation of the amine moiety on Dap (3), the side chains of the peptide were deprotected, and the peptide was subse- quently cleaved from the resin (4) by using assay buffer that contains dithiothreitol (DTT). The peptides were then filtered from the synthesis plate into a receiving plate and the 720-member library was subsequently screened.
We employed Arg-Ala-Leu-Pro-Pro-Leu-Pro as the starting point for Fyn-SH3 ligand optimization, and this sequence is consistent with most known SH3 domain binding elements. We initially introduced diversity elements on the N terminus of this peptide to furnish Library I (Figure 2) . The 720 individual members of this library were subsequently assessed for SH3 binding potency via an ELISA-based screen. The latter was performed in parallel by using strepavidin-coated 96-well plates. A biotinylated peptide SH3-directed ligand was appended to the individual wells, and a SH3 domain GST fusion protein was subsequently introduced. Competition between members of the library and the microwell bound biotinylated peptide ligand determined the extent to which the SH3 domain GST fusion protein was retained by the individual wells after washing. The latter was quantified by using an anti-GST-peroxidase fusion construct. The assay is dependent upon a strong binding interaction between the SH3 domain GST fusion protein and the biotinylated peptide ligand associated with the strepavidin-coated well. Unfortunately, as noted above, conventional peptide ligands bind modestly to SH3 domains. Consequently, we decided to prepare, for screening purposes, a variant of the peptoid series reported by Lim and his colleagues [14, 15] . Although the 13 residue-containing peptoid 5 does not discriminate between the SH3 domains of Src, and Grb2, it does exhibit a moderately good affinity for these domains (K D = w150 nM). We prepared construct 6, which contains an aminohexanoic acid (Ahx) dyad between the biotin substituent and the N-benzylated consensus sequence ( Figure 3 ). The Ahx 2 linker serves to ensure that the SH3 domain has spatial access to the microwell bound peptoid moiety. We also prepared the fluorescein-labeled analog 7, which exhibits a K D of 230 ± 30 nM for the Fyn-SH3 domain, but with little selectivity versus other members of the Src kinase family (vide infra and Table 1 ).
Our initial screen of the heptapeptide-based Library I revealed three lead derivatives. These leads were resynthesized on the Rink resin as the C-terminal amidecapped derivatives (compounds 8a-8c; Figure 4 ), purified, and their IC 50 values subsequently determined by using the ELISA assay described in the previous paragraph. Their relative affinities ranged from 15 M for the 2-hydroxynicotinic acid derivative 8a up to 45 M for the cyclopropyl derivative 8c. K D values were obtained via equilibrium dialysis by using the fluorescent intensity inherent within the nicotinic acid moiety. The K D for the lead derivative from Library I, compound 8a, is 1.2 ± 0.2 M, a nearly 15-fold improvement relative to the corresponding acetylated derivative 9 (K D = 15 ± 4 M). As expected, the parent peptide 9 is unable to discriminate between the various SH3 domains of the Src family members (Table 1) . By contrast, some selectivity in favor of Fyn is apparent with 8a, particularly with respect to the SH3 domains from Lck and Hck. With a biasing element at the N terminus of Arg-AlaLeu-Pro-Pro-Leu-Pro in place, we subsequently examined the effect of nonnatural substituents at various internal sites of the consensus sequence peptide. Specifically, three sublibraries of the peptide 8a lead containing Dap replacements at Leu-3 (Library II), Leu-6 (Library III), and at the C terminus (Library IV) were prepared. These libraries were prepared as depicted in Figure 2 . In all three cases (10a-10c), the Dap-containing 2-hydroxynicotinic acid-derivatized peptides were synthesized via an Fmoc protocol on the disulfide Tentagel resin. Following completion of the peptide framework, the Adpoc protecting group on the Dap side Table 1 ). In addition, a slight improvement in selectivity for the Fyn-SH3 domain relative to Lck and Hck is apparent, as is the emergence of discriminatory behavior versus that of Yes and Src.
Based on the optimized sequence contained in 11a, we prepared a second sublibrary containing molecular diversity introduced at the Ala-2 position. Library V contains two Dap residues, each of which must be selectively modified. A number of synthetic strategies are possible. However, given the possible reactivity of the catechol hydroxyl moieties of the Dap substituent in 11a, we decided to introduce the 2,3-dihydroxybenzoic acid moiety after completion of the peptide framework (Figure 2 ). This required the use of two different Dap residues that were differentially side chain protected. The peptide-Tentagel resin 12 was prepared via Fmoc chemistry. The Adpoc group on the C-terminal Dap residue was selectively removed with 3% CF 3 CO 2 H, and 2,3-dihydroxybenzoic acid was subsequently coupled to the free amine side chain (13). The Alloc-protected Dap moiety at position 2 was then removed with Pd O , and the resultant peptide-resin containing the free amine was distributed in equal amounts to 720 individual microwells for coupling with activated carboxylic acids (Library V). The peptide library was then side chain deprotected, extensively washed, and subsequently released from the Tentagel resin by using assay buffer. Screening of Library V furnished a single lead compound, which was resynthesized, purified, and evaluated as a ligand (14) for the SH3 domain of Fyn. As depicted in Table 1 , peptide 14 displays a K D of 25 ± 5 nM for the SH3 domain of Fyn, a nearly 1,000-fold enhanced affinity relative to the starting parent peptide 9. In addition, the former exhibits a 10-fold selective affinity for Fyn versus SH3 domains from other Src kinase family members. To the best of our knowledge, this is the first example of a ligand that is able to distin- 1H, s,  CONH), 4.62 (1H, C α H), 1.56 (2H, C β H 2 ), 1.67 (2H, C γ H 2 ) , 0.91 (2H, C δ H 2 ) for Leu-3; 4.70 (1H, C α H), 2.34 (1H, C β H), 1.90 (1H, C β H), 2.03  (2H, C γ H 2 ), 3.83 (1H, C δ H), 3.67 (1H, C δ H) 
For nonfluorescent peptide 9, the following equation was used for the determination of K d #: 
